DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
10.13
+0.30 (3.05%)
At close: May 12, 2025, 4:00 PM
10.13
0.00 (0.00%)
After-hours: May 12, 2025, 4:28 PM EDT
DBV Technologies Revenue
DBV Technologies had revenue of $753.00K in the quarter ending March 31, 2025, a decrease of -46.48%. This brings the company's revenue in the last twelve months to $3.50M, down -76.59% year-over-year. In the year 2024, DBV Technologies had annual revenue of $4.15M, down -73.61%.
Revenue (ttm)
$3.50M
Revenue Growth
-76.59%
P/S Ratio
84.43
Revenue / Employee
$31,791
Employees
110
Market Cap
295.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DBVT News
- 7 days ago - DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - GlobeNewsWire
- 12 days ago - DBV Technologies Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - GlobeNewsWire
- 6 weeks ago - DBV Technologies ADRs Rise After Up to $306.9M in New Financing - Market Watch
- 6 weeks ago - DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved - GlobeNewsWire
- 7 weeks ago - DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - GlobeNewsWire
- 4 months ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire